Goldman Sachs Group Inc Praxis Precision Medicines, Inc. Transaction History

Goldman Sachs Group Inc

$605 Billion
Q3 2024

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 May 14, 2024	BUY	$0.87 - $1.71 $80,573 - $158,368	92,613 New	92,613 $158,000
Q3 2023 Nov 14, 2023	SELL	$0.87 - $1.71 $52,998 - $104,169	-60,918 Reduced 39.68%	92,613 $158,000
Q2 2023 May 14, 2024	SELL	$0.83 - $1.18 $503,938 - $716,442	-607,155 Reduced 79.82%	153,531 $176,000
Q2 2023 Aug 14, 2023	SELL	$0.83 - $1.18 $503,938 - $716,442	-607,155 Reduced 79.82%	153,531 $176,000
Q1 2023 May 14, 2024	BUY	$0.8 - $4.98 $32,987 - $205,345	41,234 Added 5.73%	760,686 $616,000
Q1 2023 May 11, 2023	BUY	$0.8 - $4.98 $32,987 - $205,345	41,234 Added 5.73%	760,686 $616,000
Q4 2022 May 14, 2024	SELL	$1.88 - $36.45 $757,923 - $14.7 Million	-403,151 Reduced 35.91%	719,452 $1.71 Million
Q4 2022 Feb 13, 2023	SELL	$1.88 - $36.45 $757,923 - $14.7 Million	-403,151 Reduced 35.91%	719,452 $1.71 Million
Q3 2022 May 14, 2024	BUY	$2.5 - $37.95 $1.32 Million - $20 Million	526,913 Added 88.45%	1,122,603 $2.55 Million
Q3 2022 Nov 10, 2022	BUY	$2.5 - $37.95 $1.32 Million - $20 Million	526,913 Added 88.45%	1,122,603 $0
Q2 2022 May 14, 2024	BUY	$1.75 - $11.34 $1.04 Million - $6.76 Million	595,690 New	595,690 $1.46 Million
Q2 2022 Aug 15, 2022	BUY	$1.75 - $11.34 $798,245 - $5.17 Million	456,140 Added 326.86%	595,690 $1.46 Million
Q1 2022 May 16, 2022	BUY	$10.21 - $20.29 $650,009 - $1.29 Million	63,664 Added 83.89%	139,550 $1.43 Million
Q4 2021 Feb 14, 2022	SELL	$16.76 - $22.99 $552,962 - $758,509	-32,993 Reduced 30.3%	75,886 $1.5 Million
Q3 2021 Nov 10, 2021	BUY	$13.15 - $22.56 $1.43 Million - $2.46 Million	108,879 New	108,879 $2.01 Million

Others Institutions Holding PRAX

# of Institutions

Shares Held

75K

Call Options Held

Put Options Held

Tekla Capital Management LLC

75K
Shares

$5.36 Million
0.0% of portfolio

View Full List

About Praxis Precision Medicines, Inc.

Ticker PRAX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,576,100
Market Cap $3.26B
Description
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of ...

More about PRAX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Account